VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT

ConditionsOlder Patients Myeloid Malignancies Conditioning Hematopoietic Stem Cell Transplantation (HSCT)

Trial statusNot yet recruiting

Trial phasePhase 2, Phase 3

Trial typeInterventional

Biological sexAll

Age60-75

SponsorNanfang Hospital, Southern Medical University

About this trial

The purpose of this study is to compare the efficacy and safety of venetoclax+decitabine+busulfan+fludarabine (VEN+DAC+Bu2Flu4) regimen with busulfan+fludarabine (Bu2Flu5) regimen in older patients with myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Eligibility criteria

Qualifiers

60-75 years

Acute myeloid leukaemia in first complete remission or myelodysplastic syndrome

Willing to undergo the first allo-HSCT

Eastern Cooperative Oncology Group performance status of 0-2

Disqualifiers

Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)

Patients with any conditions not suitable for the trial (investigators' decision)

Trial design

Treatments tested in this trial

Venetoclax (VEN)
Decitabine (DAC)
Busulfan (Bu)
Fludarabine (Flu)
Fludarabine (Flu)

Treatment groups

160 Participants

are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Nanfang Hospital, Southern Medical University

Lead sponsor

Source ClinicalTrials.gov